Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Neuropeptides and oligopeptidases in schizophrenia

Full text
Author(s):
Rodriguez, Benjamin [1] ; Nani, Joao Victor [1, 2] ; Almeida, Priscila G. C. [1] ; Brietzke, Elisa [3] ; Lee, Richard S. [4] ; Hayashi, Mirian A. F. [1, 2]
Total Authors: 6
Affiliation:
[1] Univ Fed Sao Paulo UNIFESP, Dept Farmacol, Escola Paulista Med, Rua 3 Maio 100, Ed INFAR, 3rd Floor, BR-04044020 Sao Paulo, SP - Brazil
[2] Natl Inst Translat Med INCT TM, CNPq FAPESP CAPES, Ribeirao Preto - Brazil
[3] Queens Univ, Dept Psychiat, Sch Med, Kingston, ON - Canada
[4] Johns Hopkins Univ, Dept Psychiat, Baltimore, MD - USA
Total Affiliations: 4
Document type: Journal article
Source: NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS; v. 108, p. 679-693, JAN 2020.
Web of Science Citations: 0
Abstract

Schizophrenia (SCZ) is a complex psychiatric disorder with severe impact on patient's livelihood. In the last years, the importance of neuropeptides in SCZ and other CNS disorders has been recognized, mainly due to their ability to modulate the signaling of classical monoaminergic neurotransmitters as dopamine. In addition, a class of enzymes coined as oligopeptidases are able to cleave several of these neuropeptides, and their potential implication in SCZ was also demonstrated. Interestingly, these enzymes are able to play roles as modulators of neuropeptidergic systems, and they were also implicated in neurogenesis, neurite outgrowth, neuron migration, and therefore, in neurodevelopment and brain formation. Altered activity of oligopeptidases in SCZ was described only more recently, suggesting their possible utility as biomarkers for mental disorders diagnosis or treatment response. We provide here an updated and comprehensive review on neuropeptides and oligopeptidases involved in mental disorders, aiming to attract the attention of physicians to the potential of targeting this system for improving the therapy and for understanding the neurobiology underlying mental disorders as SCZ. (AU)

FAPESP's process: 14/50867-3 - INCT 2014: National Institute of Science and Technology in Bioanalysis
Grantee:Lauro Tatsuo Kubota
Support type: Research Projects - Thematic Grants
FAPESP's process: 14/50891-1 - INCT 2014: Translational Medicine
Grantee:Jaime Eduardo Cecilio Hallak
Support type: Research Projects - Thematic Grants
FAPESP's process: 17/02413-1 - Validation of crotamine as a biomarker and evaluation of its potential use in the therapy of human diseases
Grantee:Mirian Akemi Furuie Hayashi
Support type: Regular Research Grants
FAPESP's process: 14/18938-8 - Metabolomic profiling of severe mental disorders using Nuclear Magnetic Ressonance (NMR)
Grantee:Ljubica Tasic
Support type: Regular Research Grants
FAPESP's process: 19/09207-3 - Study of molecular and cellular mechanisms in mental disorders
Grantee:João Victor Silva Nani
Support type: Scholarships in Brazil - Doctorate